All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

palopegteriparatide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
parathyroid hormone analogues; peptides and glycopeptides	5834	None

Description:

Molecule	Description
Molfile Synonyms: palopegteriparatide yorvipath transcon pth	Palopegteriparatide is a prodrug of parathyroid hormone (PTH[1-34]). Palopegteriparatide is designed to provide continuous exposure to PTH(1-34), which activates the PTH1 receptor. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
Aug. 9, 2024	FDA	Ascendis Pharma Bone
Aug. 25, 2025	PMDA	Teijin Pharma Limited

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H05AA05	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS CALCIUM HOMEOSTASIS PARATHYROID HORMONES AND ANALOGUES Parathyroid hormones and analogues

Related Drugs by ATC class:

H05AA Parathyroid hormones and analogues 3 drugs

abaloparatideparathyroid hormoneteriparatide

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypoparathyroidism	indication	36976004	DOID:11199

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	8906847	April 30, 2031	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	8906847	April 30, 2031	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	8906847	April 30, 2031	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	11590207	Sept. 28, 2037	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	11857603	Sept. 28, 2037	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	12295989	Sept. 28, 2037	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	12453778	Sept. 28, 2037	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	11590207	Sept. 28, 2037	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	11857603	Sept. 28, 2037	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	12295989	Sept. 28, 2037	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	12453778	Sept. 28, 2037	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	11590207	Sept. 28, 2037	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	11857603	Sept. 28, 2037	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	12295989	Sept. 28, 2037	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	12453778	Sept. 28, 2037	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	12403182	Nov. 12, 2042	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	12403182	Nov. 12, 2042	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	12403182	Nov. 12, 2042	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	Aug. 9, 2029	NEW CHEMICAL ENTITY
EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	Aug. 9, 2029	NEW CHEMICAL ENTITY
EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	Aug. 9, 2029	NEW CHEMICAL ENTITY
EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	Aug. 9, 2031	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	Aug. 9, 2031	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	YORVIPATH	ASCENDIS PHARMA BONE	N216490	Aug. 9, 2024	RX	SOLUTION	SUBCUTANEOUS	Aug. 9, 2031	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Parathyroid hormone/parathyroid hormone-related peptide receptor	GPCR	Q03431	PTH1R_HUMAN		Kd	5.38		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
2222514-07-8	SECONDARY_CAS_RN
CHEMBL5095475	ChEMBL_ID
C000731747	MESH_SUPPLEMENTAL_RECORD_UI
4043376	VANDF
C5557539	UMLSCUI
CHEBI:759036	CHEBI
11060	INN_ID
d10211	MMSL
13484	IUPHAR_LIGAND_ID
G2N64C3385	UNII
2693635	RXNORM
43996711000001104	SNOMEDCT_US
D12395	KEGG_DRUG
019831	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Yorvipath	HUMAN PRESCRIPTION DRUG LABEL	1	73362-100	INJECTION, SOLUTION	168 ug	SUBCUTANEOUS	NDA	32 sections
Yorvipath	HUMAN PRESCRIPTION DRUG LABEL	1	73362-100	INJECTION, SOLUTION	168 ug	SUBCUTANEOUS	NDA	32 sections
Yorvipath	HUMAN PRESCRIPTION DRUG LABEL	1	73362-101	INJECTION, SOLUTION	294 ug	SUBCUTANEOUS	NDA	32 sections
Yorvipath	HUMAN PRESCRIPTION DRUG LABEL	1	73362-101	INJECTION, SOLUTION	294 ug	SUBCUTANEOUS	NDA	32 sections
Yorvipath	HUMAN PRESCRIPTION DRUG LABEL	1	73362-102	INJECTION, SOLUTION	420 ug	SUBCUTANEOUS	NDA	32 sections
Yorvipath	HUMAN PRESCRIPTION DRUG LABEL	1	73362-102	INJECTION, SOLUTION	420 ug	SUBCUTANEOUS	NDA	32 sections